Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) have been assigned an average recommendation of “Buy” from the ten research firms that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $23.00.

Several analysts have weighed in on STOK shares. Needham & Company LLC reissued a “buy” rating and set a $22.00 target price on shares of Stoke Therapeutics in a research report on Tuesday, February 18th. Chardan Capital reissued a “buy” rating and set a $24.00 target price on shares of Stoke Therapeutics in a research report on Wednesday, February 19th. Cantor Fitzgerald reissued an “overweight” rating on shares of Stoke Therapeutics in a research report on Tuesday, December 10th. Finally, HC Wainwright boosted their target price on shares of Stoke Therapeutics from $35.00 to $47.00 and gave the stock a “buy” rating in a research report on Tuesday, February 18th.

Insider Buying and Selling at Stoke Therapeutics

In other Stoke Therapeutics news, insider Barry Ticho sold 2,586 shares of Stoke Therapeutics stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $12.99, for a total transaction of $33,592.14. Following the completion of the sale, the insider now directly owns 44,746 shares in the company, valued at approximately $581,250.54. The trade was a 5.46 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Edward M. Md Kaye sold 6,170 shares of Stoke Therapeutics stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $12.78, for a total transaction of $78,852.60. Following the sale, the chief executive officer now owns 68,671 shares of the company’s stock, valued at approximately $877,615.38. The trade was a 8.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 62,849 shares of company stock worth $809,421. Company insiders own 11.30% of the company’s stock.

Hedge Funds Weigh In On Stoke Therapeutics

Large investors have recently made changes to their positions in the company. Barclays PLC lifted its stake in shares of Stoke Therapeutics by 145.3% in the 3rd quarter. Barclays PLC now owns 79,740 shares of the company’s stock valued at $980,000 after purchasing an additional 47,239 shares during the period. Geode Capital Management LLC lifted its stake in shares of Stoke Therapeutics by 9.7% in the 3rd quarter. Geode Capital Management LLC now owns 870,831 shares of the company’s stock valued at $10,705,000 after purchasing an additional 76,661 shares during the period. State Street Corp lifted its stake in shares of Stoke Therapeutics by 8.6% in the 3rd quarter. State Street Corp now owns 1,728,888 shares of the company’s stock valued at $21,248,000 after purchasing an additional 137,145 shares during the period. BNP Paribas Financial Markets lifted its stake in shares of Stoke Therapeutics by 1,589.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 76,154 shares of the company’s stock valued at $936,000 after purchasing an additional 71,647 shares during the period. Finally, RTW Investments LP lifted its stake in shares of Stoke Therapeutics by 10.1% in the 3rd quarter. RTW Investments LP now owns 4,652,285 shares of the company’s stock valued at $57,177,000 after purchasing an additional 427,447 shares during the period.

Stoke Therapeutics Stock Down 1.8 %

Shares of Stoke Therapeutics stock opened at $7.85 on Tuesday. The firm’s 50 day moving average price is $10.20 and its 200-day moving average price is $12.06. Stoke Therapeutics has a 52-week low of $5.60 and a 52-week high of $17.58. The company has a market cap of $415.79 million, a P/E ratio of -3.74 and a beta of 0.95.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.